- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Gastroenterology Research and Practice
Volume 2012 (2012), Article ID 595970, 7 pages
High Prevalence but Insufficient Treatment of Iron-Deficiency Anemia in Patients with Inflammatory Bowel Disease: Results of a Population-Based Cohort
Department of Internal Medicine I, University of Regensburg, 93042 Regensburg, Germany
Received 13 May 2012; Accepted 18 June 2012
Academic Editor: P. Gionchetti
Copyright © 2012 Claudia Ott et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- D. K. Podolsky, “Inflammatory bowel disease,” The New England Journal of Medicine, vol. 347, no. 6, pp. 417–429, 2002.
- C. W. Wells, S. Lewis, J. R. Barton, and S. Corbett, “Effects of changes in hemoglobin level on quality of life and cognitive function in inflammatory bowel disease patients,” Inflammatory Bowel Diseases, vol. 12, no. 2, pp. 123–130, 2006.
- L. T. Pizzi, C. M. Weston, N. I. Goldfarb et al., “Impact of chronic conditions on quality of life in patients with inflammatory bowel disease,” Inflammatory Bowel Diseases, vol. 12, no. 1, pp. 47–52, 2006.
- C. Gasche, M. C. Lomer, I. Cavill, and G. Weiss, “Iron, anaemia, and inflammatory bowel diseases,” Gut, vol. 53, no. 8, pp. 1190–1197, 2004.
- A. D. de Silva, M. Mylonaki, and D. S. Rampton, “Oral iron therapy in inflammatory bowel disease: usage, tolerance, and efficacy,” Inflammatory Bowel Diseases, vol. 9, no. 5, pp. 316–320, 2003.
- G. Bergamaschi, A. Di Sabatino, R. Albertini et al., “Prevalence and pathogenesis of anemia in inflammatory bowel disease. Influence of anti-tumor necrosis factor-α treatment,” Haematologica, vol. 95, no. 2, pp. 199–205, 2010.
- S. Kulnigg and C. Gasche, “Systematic review: managing anaemia in Crohn's disease,” Alimentary Pharmacology and Therapeutics, vol. 24, no. 11-12, pp. 1507–1523, 2006.
- C. Ott, F. Obermeier, S. Thieler et al., “The incidence of inflammatory bowel disease in a rural region of Southern Germany: a prospective population-based study,” European Journal of Gastroenterology and Hepatology, vol. 20, no. 9, pp. 917–923, 2008.
- S. Giannini and C. Martes, “Anemia in inflammatory bowel disease,” Minerva Gastroenterologica e Dietologica, vol. 52, no. 3, pp. 275–291, 2006.
- A. Wilson, E. Reyes, and J. Ofman, “Prevalence and outcomes of anemia in inflammatory bowel disease: a systematic review of the literature,” American Journal of Medicine, vol. 116, supplement 7, pp. 44S–49S, 2004.
- F. Gomollón and J. P. Gisbert, “Anemia and inflammatory bowel diseases,” World Journal of Gastroenterology, vol. 15, no. 37, pp. 4659–4665, 2009.
- G. Weiss and L. T. Goodnough, “Anemia of chronic disease,” The New England Journal of Medicine, vol. 352, no. 10, pp. 1011–1023, 2005.
- C. Gasche, A. Berstad, R. Befrits et al., “Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases,” Inflammatory Bowel Diseases, vol. 13, no. 12, pp. 1545–1553, 2007.
- C. Gasche, R. Evstatiev, T. Haas et al., “Diagnosis and treatment of iron deficiency and anaemia in inflammatory bowel diseasesconsensus of the Austrian IBD Working Party,” Zeitschrift fur Gastroenterologie, vol. 49, no. 5, pp. 627–632, 2011.
- M. Voegtlin, S. R. Vavricka, A. M. Schoepfer et al., “Prevalence of anaemia in inflammatory bowel disease in Switzerland: a cross-sectional study in patients from private practices and university hospitals,” Journal of Crohn's and Colitis, vol. 4, no. 6, pp. 642–648, 2010.
- J. P. Gisbert, F. Bermejo, R. Pajares et al., “Oral and intravenous iron treatment in inflammatory bowel disease: hematological response and quality of life improvement,” Inflammatory Bowel Diseases, vol. 15, no. 10, pp. 1485–1491, 2009.
- A. Khalil, J. R. Goodhand, M. Wahed, J. Yeung, F. R. Ali, and D. S. Rampton, “Efficacy and tolerability of intravenous iron dextran and oral iron in inflammatory bowel disease: a case-matched study in clinical practice,” European Journal of Gastroenterology & Hepatology, vol. 23, no. 11, pp. 1029–1035, 2011.
- O. Schröder, O. Mickisch, U. Seidler et al., “Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease—a randomized, controlled, open-label, multicenter study,” American Journal of Gastroenterology, vol. 100, no. 11, pp. 2503–2509, 2005.
- M. Auerbach, H. Ballard, and J. Glaspy, “Clinical update: intravenous iron for anaemia,” The Lancet, vol. 369, no. 9572, pp. 1502–1504, 2007.
- S. Kulnigg, S. Stoinov, V. Simanenkov et al., “A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial,” American Journal of Gastroenterology, vol. 103, no. 5, pp. 1182–1192, 2008.
- S. Lindgren, O. Wikman, R. Befrits et al., “Intravenous iron sucrose is superior to oral iron sulphate for correcting anaemia and restoring iron stores in IBD patients: a randomized, controlled, evaluator-blind, multicentre study,” Scandinavian Journal of Gastroenterology, vol. 44, no. 7, pp. 838–845, 2009.
- C. Leitgeb, M. Pecherstorfer, E. Fritz, and H. Ludwig, “Quality of life in chronic anemia of during treatment with recombinant human erythropoietin,” Cancer, vol. 73, no. 10, pp. 2535–2542, 1994.